AlloSure Lung detects early molecular signs of lung allograft injury, supporting earlier, more informed clinical decision-making.³⁻⁷
AlloSure detects critical molecular signs of injury³⁻⁶
Increased AlloSure levels are associated with the underlying causes that can lead to ALAD, and eventually CLAD¹
AlloHome: real-time monitoring to complement early detection with AlloSure
Trusted by lung transplant programs nationwide
AlloSure tests have been performed across kidney, heart, and lung patients
Molecular tests delivered to transplant physicians
Resources
Incorporating AlloSure into your workflow
How to Order AlloSure
Find the steps needed to place an order, with ordering options that fit your center.
Interpretation Guides
Access practical guidance for understanding and interpreting results.
Downloads
Quick Instructions: Drawing AlloSure Specimens
Key steps and requirements for AlloSure specimen collection and preparation.
Webinars
Events
Connect with our team to learn more about AlloSure Lung
Napoli C, Benincasa G, Fiorelli A, et al. Lung transplantation: current insights and outcomes. Transpl Immunol. 2024;85:102073.
Diel R, Simon S, Gottlieb J. Chronic lung allograft dysfunction is associated with significant disability after lung transplantation¬¬–a burden of disease burden analysis in 1025 cases. Adv Respir Med. 2023;91(5):432-444.
Keller MB, Newman D, Alnababteh M, et al. Extreme elevations of donor-derived cell-free DNA increases the risk of chronic lung allograft dysfunction and death, even without clinical manifestations of disease. J Heart Lung Transplant. 2024;43(9):1374-1382.
Trindade AJ, Chapin KC, Gray JN, et al. Relative change in donor-derived cell-free DNA is superior to absolute values for diagnosis of acute lung allograft dysfunction. Transplant Direct. 2023;9(6):e1487.
Ju C, Xu X, Zhang J, et al. Application of plasma donor-derived cell free DNA for lung allograft rejection diagnosis in lung transplant recipients. BMC Pulm Med. 2023;23(1):37.
Khush KK, De Vlaminck I, Luikart H, Ross DJ, Nicolls MR. Donor-derived, cell-free DNA levels by next-generation targeted sequencing are elevated in allograft rejection after lung transplantation. ERJ Open Res. 2021;7(1):00462-00202.
Keller M, Sun J, Mutebi C, et al. Donor-derived cell-free DNA as a composite marker of acute lung allograft dysfunction in clinical care. J Heart Lung Transplant. 2022;41(4):458-466.
Keller MB, Newman D, Alnababeteh M, et al. Molecular criteria for pulmonary antibody-mediated rejection are associated with an increased risk of allograft failure. J Heart Lung Transplant. 2025;44(10):1535-1542.
Sayah D, Weigt SS, Ramsey A, Ardehali A, Golden J, Ross DJ. Plasma donor-derived cell-free DNA levels are increased during acute cellular rejection after lung transplant: pilot data. Transplant Direct. 2020;6(10):e608.